Cargando…

Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia

OBJECTIVES: Historical records of influenza pandemics demonstrate variability in incidence and severity between waves. The influenza A(H1N1)pdm09 pandemic was the first in which many countries implemented strain-specific vaccination to mitigate subsequent seasons. Serosurveys provide opportunity to...

Descripción completa

Detalles Bibliográficos
Autores principales: McVernon, Jodie, Laurie, Karen, Faddy, Helen, Irving, David, Nolan, Terry, Barr, Ian, Kelso, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186467/
https://www.ncbi.nlm.nih.gov/pubmed/24382379
http://dx.doi.org/10.1111/irv.12225
_version_ 1782338067595526144
author McVernon, Jodie
Laurie, Karen
Faddy, Helen
Irving, David
Nolan, Terry
Barr, Ian
Kelso, Anne
author_facet McVernon, Jodie
Laurie, Karen
Faddy, Helen
Irving, David
Nolan, Terry
Barr, Ian
Kelso, Anne
author_sort McVernon, Jodie
collection PubMed
description OBJECTIVES: Historical records of influenza pandemics demonstrate variability in incidence and severity between waves. The influenza A(H1N1)pdm09 pandemic was the first in which many countries implemented strain-specific vaccination to mitigate subsequent seasons. Serosurveys provide opportunity to examine the constraining influence of antibody on population disease experience. DESIGN: Changes in the proportion of adults seropositive to influenza A(H1N1)pdm09over the 2009/10 (summer) interepidemic period and 2010 (winter) influenza season were measured to determine whether there was a temporal relationship with vaccine distribution and influenza activity, respectively. SETTING: Australia. SAMPLE: Plasma samples were collected from healthy blood donors from seven cities at the end of the first wave (November 2009), and before (March/April 2010) and after (November 2010) the subsequent influenza season. MAIN OUTCOME MEASURES: Haemagglutination inhibition (HI) assays were performed to assess reactivity of plasma against A(H1N1)pdm09, and the proportion seropositive (HI titre ≥ 40) compared over time, by age group and location. RESULTS: Between the 2009 and 2010 influenza seasons, the seropositive proportion rose from 22% to 43%, an increase observed across all ages and sites. Brisbane alone recorded a significant rise in seropositivity over the 2010 influenza season – from a baseline of 35% to 53%. The seropositive proportion elsewhere was ≥40% pre-season, and did not rise over winter. CONCLUSIONS: A vaccine-associated increase in seropositive proportion preceding the influenza season correlated with low levels of disease activity in winter 2010. These observations support the role of immunisation in mitigating the ‘second wave’ of A(H1N1)pdm09, with timing critical to ensure sustained herd protection.
format Online
Article
Text
id pubmed-4186467
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-41864672014-10-29 Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia McVernon, Jodie Laurie, Karen Faddy, Helen Irving, David Nolan, Terry Barr, Ian Kelso, Anne Influenza Other Respir Viruses Original Articles OBJECTIVES: Historical records of influenza pandemics demonstrate variability in incidence and severity between waves. The influenza A(H1N1)pdm09 pandemic was the first in which many countries implemented strain-specific vaccination to mitigate subsequent seasons. Serosurveys provide opportunity to examine the constraining influence of antibody on population disease experience. DESIGN: Changes in the proportion of adults seropositive to influenza A(H1N1)pdm09over the 2009/10 (summer) interepidemic period and 2010 (winter) influenza season were measured to determine whether there was a temporal relationship with vaccine distribution and influenza activity, respectively. SETTING: Australia. SAMPLE: Plasma samples were collected from healthy blood donors from seven cities at the end of the first wave (November 2009), and before (March/April 2010) and after (November 2010) the subsequent influenza season. MAIN OUTCOME MEASURES: Haemagglutination inhibition (HI) assays were performed to assess reactivity of plasma against A(H1N1)pdm09, and the proportion seropositive (HI titre ≥ 40) compared over time, by age group and location. RESULTS: Between the 2009 and 2010 influenza seasons, the seropositive proportion rose from 22% to 43%, an increase observed across all ages and sites. Brisbane alone recorded a significant rise in seropositivity over the 2010 influenza season – from a baseline of 35% to 53%. The seropositive proportion elsewhere was ≥40% pre-season, and did not rise over winter. CONCLUSIONS: A vaccine-associated increase in seropositive proportion preceding the influenza season correlated with low levels of disease activity in winter 2010. These observations support the role of immunisation in mitigating the ‘second wave’ of A(H1N1)pdm09, with timing critical to ensure sustained herd protection. Blackwell Publishing Ltd 2014-03 2013-12-31 /pmc/articles/PMC4186467/ /pubmed/24382379 http://dx.doi.org/10.1111/irv.12225 Text en © 2013 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
McVernon, Jodie
Laurie, Karen
Faddy, Helen
Irving, David
Nolan, Terry
Barr, Ian
Kelso, Anne
Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia
title Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia
title_full Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia
title_fullStr Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia
title_full_unstemmed Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia
title_short Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia
title_sort seroprevalence of antibody to influenza a(h1n1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in australia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186467/
https://www.ncbi.nlm.nih.gov/pubmed/24382379
http://dx.doi.org/10.1111/irv.12225
work_keys_str_mv AT mcvernonjodie seroprevalenceofantibodytoinfluenzaah1n1pdm09attributedtovaccinationorinfectionbeforeandafterthesecond2010pandemicwaveinaustralia
AT lauriekaren seroprevalenceofantibodytoinfluenzaah1n1pdm09attributedtovaccinationorinfectionbeforeandafterthesecond2010pandemicwaveinaustralia
AT faddyhelen seroprevalenceofantibodytoinfluenzaah1n1pdm09attributedtovaccinationorinfectionbeforeandafterthesecond2010pandemicwaveinaustralia
AT irvingdavid seroprevalenceofantibodytoinfluenzaah1n1pdm09attributedtovaccinationorinfectionbeforeandafterthesecond2010pandemicwaveinaustralia
AT nolanterry seroprevalenceofantibodytoinfluenzaah1n1pdm09attributedtovaccinationorinfectionbeforeandafterthesecond2010pandemicwaveinaustralia
AT barrian seroprevalenceofantibodytoinfluenzaah1n1pdm09attributedtovaccinationorinfectionbeforeandafterthesecond2010pandemicwaveinaustralia
AT kelsoanne seroprevalenceofantibodytoinfluenzaah1n1pdm09attributedtovaccinationorinfectionbeforeandafterthesecond2010pandemicwaveinaustralia